Verified Clinical Trials Launches in Japan in Partnership with Medical Revolutions Japan (MRJ) and JACIC to Prevent Duplicate and Professional Subjects in Clinical Trials
'No clinical trial or geography is immune to the challenge of duplicate subjects—it's a global phenomenon. Our system provides an effective, scalable solution.'
For the past thirty years, Japan's only system for preventing duplicate subject registration was developed by JACIC and used across Phase 1 studies. However, a recent review concluded that the system requires substantial modernization to meet international standards and support the growing number of global clinical trials. In addition, duplicate subjects in clinical trials have become a growing concern in Phase II and Phase III trials as well. After extensive evaluation, the VCT platform—widely adopted as the global standard—was selected as the best solution and replacement.
With the support of MRJ, which was commissioned by JACIC to assist with domestic implementation, Verified Clinical Trials has begun initiating sites in Japan, with additional sites expected to join in the coming weeks and months. These sites will benefit from the biometric capabilities of the VCT system, offering a higher level of subject authentication and protocol compliance. This rollout will include sites conducting Phase I through Phase IV clinical trials.
'Given the sophisticated functionality and biometric identification capability of the VCT system, as well as its proven match for other Asian countries,' a representative of MRJ commented, 'I believe it is destined to become the new Japan standard for duplicate subject registration prevention.'
Verified Clinical Trials brings to Japan a cross-sponsor, cross-therapeutic area subject registry already in use in up to 40 countries. The platform not only detects but also prevents duplicate subjects and other protocol violations at the time of screening—and maintains protections throughout the entire duration of the trial.
'We're honored to bring VCT to Japan as part of a shared mission to raise the standard of subject protection and trial integrity,' said Mitchell Efros, MD, President and CEO of Verified Clinical Trials. 'No clinical trial or geography is immune to the challenge of duplicate subjects—it's a global phenomenon. Our system provides an effective, scalable solution.'
' By introducing VCT in Japan, sponsors gain a real-time tool to proactively manage protocol risk and ensure only qualified participants are enrolled,' added Kerri Weingard, ANP, Vice President and Chief Operating Officer of Verified Clinical Trials.
'This launch represents our commitment to regulatory excellence and regional partnership across the APAC region,' said Eve Hsu, Global Regulatory Director at Verified Clinical Trials. 'With dedicated team members based throughout APAC, we're well-positioned to support sites and sponsors locally and help elevate clinical trial quality and compliance across the region.'
The VCT system was co-founded by Mitchell Efros, MD, and Kerri Weingard, ANP, both experienced clinical researchers who developed the registry to address long-standing challenges in subject eligibility, data quality, and compliance.
About Verified Clinical Trials (VCT)
Verified Clinical Trials is the world's largest research subject database registry designed to detect and prevent duplicate and professional subjects in clinical trials. VCT fills a critical gap in the clinical research industry by providing insight into a research subject's past trial participation. This enables better subject selection and helps ensure successful clinical trial execution. Active in up to 40 countries, VCT supports sponsors, CROs, and research sites across all trial phases and therapeutic areas, enhancing data quality, subject safety, and protocol compliance.
About Medical Revolutions Japan (MRJ)
Medical Revolutions Japan is a clinical trial consultancy managed and staffed by industry experts with long and rich experience in all facets of clinical development and research in the Japanese market. Founded in 2024 as an affiliate of Keikokai Medical Corporation, a longstanding clinical research unit operator in Tokyo, MRJ is currently expanding its global client base and working to connect both international and local players to help the domestic Japanese clinical development industry rise to the challenges brought about by technological disruptions as it continues to grow and internationalize.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Buzz Feed
10 hours ago
- Buzz Feed
Popular Habits That Are Actually Extremely Unhygienic
We all like to think we have good hygiene habits, but even the most hygiene-conscious person has a few eating, cooking, cleaning, and social habits that have become so normalized it's easy to forget how unhygienic they probably are. Specialist-Rise4952 on Reddit asked, "What is extremely unhygienic but everyone seems to do it anyway?" And some of these would make a germaphobic person absolutely CRINGE. Here are some of the responses: "Wearing nitrile gloves to prepare food then touching everything else including money." —Waste-Entry850 "Eating finger food while bowling." —_Keys2theWest_ "Using makeup testers in the store like lipstick or mascara without using a disposable wand or using the available hygiene spray to spray off the product first." —BleghYeeHaw "Public bathroom door handles. Many people don't wash their hands. But after you washed your hands, the very next thing you have to do is grab the filthy handle." —baden27 "Licking fingers at places where you serve yourself food. I worked for a buffet restaurant, and the number of people who lick their fingers and then grab the serving utensils right after is disgusting." —Thunbbreaker4 "Putting your whole mouth over the water fountain." —DinkandDrunk "Not sure if this is universal, but I've noticed friends/family with babies don't wash their hands after changing their diapers. I definitely silently judge them for it!" —vellen890 "Licking your fingers, then counting money." —otterlytatts "Beer pong." —Potential_Speed_7048 "The open-mouth cough. We learned nothing." —chrismasto "Toilet keys kept behind the counter in cafes and handed to you by staff who don't wash their hands after handing you the key!!" —No-Age4007 "As someone who's Asian, I'm disgusted seeing people wear shoes in their houses (not the house slipper kind). I know it's not my house, and those are not my feet, but damn, that's disgusting." —SmithDoesGaming "Blowing multiple candles off a birthday cake!!!" —nebbish79 "Drinking from cans without wiping the tops first." —sporesatemygoldfish "Not sanitizing their phone and taking it everywhere with them, including to bed. Your phone is incredibly dirty!" —yuujinnie "Chopping vegetables on a chicken-contaminated chopping board." —Ayilari "People in restaurants, at the end of the meal, blowing their nose into the serviette then leaving it on their plate for the server to pick up. It's so gross, and so many people do it." —SheetsTinks "Leaving the toilet seat up. Poo particles everywhere now." —llamallama92 "The pharmacy credit card machine, where every last person is required to touch the same stylus to sign their names for receipt." —EthanDMatthews "Shaking hands." —Prize_Proof5332 "Swimming in natural waters. If you take the time to slow down and look, there are hundreds of little critters and bugs everywhere that are all over you. Not to mention the animal excrement, anything people throw off boats, or anything that gets dumped. Regardless, very fun and I'll never stop, lol." —Timely_Thing2829 "The five-second rule." —StrangeCosmolian "Kissing pets. Letting them lick you and not washing the area after." —absurdlycurious "People with water bottles who use refill stations and touch the mouth of their bottle to the spout." —Weary_Ocelot_3456 "Air hand dryers. Millions of pee and poop-particles blowing everywhere. Ew." —Porch-Lettuce "Wearing clothes from the store without washing them. I work in retail at one of those discount stores and I process all lot of clothes. They've been dropped on the floor a lot and many hands probably touched that same article of clothing in one given day." —axia_1214 "Not actually washing your feet when you shower. 'Water will get it' doesn't work, people!" —Jlx_27 "Touching elevator buttons!" —Prestigious_War7354 "Eating candy from the containers where you help yourself to what you want." —kormakarma95 "Not masking up when you're sick." —HowAboutThatUsername "Acrylic nails. They're very rarely 100% sealed to your actual nail at the bottom. The amount of filth I've seen under them." —itisme_cc "What is it called, Apple bobbing? You're literally dunking your head into a barrel of kids' sweat and spit-filled back-washed water for a chance to fish a possibly nibbled and sickly apple." —CuriousWebz "Passing a joint around." —red_langford And lastly, "Ball pits." —Princess_Cake22 Have you done any of these? Are there things that should be added to this list? Let us know in the comments!
Business Wire
a day ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
